证券代码：002864 证券简称：盘龙药业 编号：2022-11-02-2 | --- | --- | --- | |-------------------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | | | | | | √ 特定对象调研 | □分析师会议 | | 投资者关系活 | □媒体采访 □业绩说明会 | | | 动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 国泰基金、华安证券 | | | 时间 | 2022 年 11 月 02 | 日（星期三） 13:30-15:00 | | 地点 | 线上电话会议 | | | 上市公司接待 人员姓名 | | 集团副总经理兼董秘吴杰先生、集团财务总监祝凤鸣先生、集 ...

陕西盘龙药业集团股份有限公司 2022 年第三季度报告 | 证券代码：002864 | 证券简称：盘龙药业 | 公告编号：2022-074 | | --- | --- | --- | | 债券代码：127057 | 债券简称：盘龙转债 | | 陕西盘龙药业集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 上年同期增减 | | 营业收入（元） | 262,473,046.87 | 18.6 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 430,974,648.13, representing a 7.34% increase compared to CNY 401,509,288.02 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 44,869,565.56, up 5.77% from CNY 42,421,208.12 in the previous year[20]. - The net cash flow from operating activities increased significantly by 92.76%, reaching CNY 72,461,969.55 compared to CNY 37,592,606.02 in the same period last year[20]. - Total assets at the end of the reporting period were CNY 1,703,234,168.93, a 28.05% increase from CNY 1,330,174,616.17 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 10.02%, amounting to CNY 870,687,970.34 compared to CNY 791,384,719.19 at the end of the previous year[20]. - Basic earnings per share rose to CNY 0.52, reflecting a 4.00% increase from CNY 0.50 in the same period last year[20]. - The weighted average return on net assets was 5.37%, a slight decrease of 0.43% from 5.80% in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 46,402,156.75, which is a 4.82% increase from CNY 44,270,183.01 in the previous year[20]. Product Development and Market Position - The company’s main product, Panlong Qipian, is a Class A National Medical Insurance drug targeting chronic diseases, particularly among the elderly[30]. - The market for chronic disease medications is expected to grow significantly, with approximately 190 million elderly individuals suffering from chronic illnesses in China[30]. - The company plans to enhance its product offerings in response to the increasing demand for chronic disease management[31]. - The company is focusing on expanding its market presence and enhancing its research and development capabilities in traditional Chinese medicine[32]. - The company has reported a strong product lineup with over 100 specifications across 9 functional categories, primarily led by the patented "Panlong Qipian"[36]. - "Panlong Qipian" ranked second in market share for traditional Chinese medicine in the field of musculoskeletal diseases in 2021, with a market share of 6.87%[38]. - The company has developed a series of health products, including toothpaste and face masks, under the "Panlong Seven" brand, which have been well received by consumers[67]. Research and Development - The company is actively involved in research and development to improve the efficacy and safety of its products, supported by clinical studies[41]. - The company has developed a new class of chemical innovative drugs for treating COVID-19, currently in the preclinical research stage[48]. - The company completed the registration of 6 medical institution formulations and has 3 under technical review, while 2 have completed pilot studies[48]. - The company has established a knowledge management system for intellectual property, enhancing its competitive edge in the market[50]. - The company has completed the issuance of convertible bonds on March 3, 2022, and listed them on April 8, 2022, facilitating capital market interactions[54]. Corporate Governance and Compliance - The company emphasizes quality management and has maintained a zero-accident record in product safety for several years[118]. - The company has established a robust communication mechanism with investors to ensure transparency and protect their rights[120]. - The company has committed to measures to mitigate the dilution of immediate returns from public stock issuance, with management promising to act in the best interests of shareholders[135]. - The company has not engaged in any significant related party transactions during the reporting period[148]. - The company has confirmed that there are no issues with the management and use of raised funds, ensuring compliance with regulations[101]. Social Responsibility and Community Engagement - The company donated 430,000 RMB to support the purchase of two ambulances for a local hospital as part of its social responsibility initiatives[122]. - During the pandemic, the company contributed 225,000 RMB in medical supplies and funds to various organizations for epidemic prevention efforts[122]. - The company has engaged over 7,520 individuals in poverty alleviation efforts, creating stable income channels for them[123]. - The company is actively involved in the "Ten Thousand Enterprises Help Ten Thousand Villages" initiative, promoting the integration of poverty alleviation and rural revitalization[124]. - The company aims to expand the planting area of traditional Chinese medicinal herbs, including Dan Shen and Ban Lan Gen, to support rural communities[125]. Financial Management and Investment - The financing activities generated cash inflow of ¥314,499,749.58, a significant increase of 1,953.55% due to the issuance of convertible bonds and increased bank loans[78]. - The company has made a new equity investment of 1,000,000.00 in a health service company, holding a 60% stake[90]. - The total amount of raised funds is CNY 456,032,581.13, with CNY 233,632,868.71 used by June 30, 2022, leaving CNY 241,283,581.95 unutilized[96]. - The company has established a comprehensive marketing network covering over 3,500 hospitals and 4,000 pharmacies across 31 provinces in China[73]. - The company has implemented a refined management system through ERP, enhancing production and material management efficiency[72].

Financial Performance - The company's revenue for Q1 2022 was CNY 198,828,511.27, representing a 13.70% increase compared to CNY 174,868,139.36 in the same period last year[5] - Net profit attributable to shareholders was CNY 20,081,539.34, up 13.21% from CNY 17,738,938.74 year-on-year[5] - Total operating revenue for Q1 2022 was CNY 198,828,511.27, an increase of 13.71% compared to CNY 174,868,139.36 in Q1 2021[23] - Net profit for Q1 2022 reached CNY 20,311,464.87, representing a growth of 10.34% from CNY 18,406,264.02 in Q1 2021[24] - The company reported a total profit of CNY 23,491,843.47 for Q1 2022, an increase from CNY 21,836,219.91 in Q1 2021[24] Cash Flow - The net cash flow from operating activities surged by 777.18% to CNY 39,416,073.24, compared to CNY 4,493,507.22 in the previous year[5] - Cash flow from operating activities for Q1 2022 was CNY 39,416,073.24, significantly higher than CNY 4,493,507.22 in Q1 2021[26] - The net cash flow from investing activities was -¥19,593,205.50, compared to -¥17,669,998.29 in the previous year, indicating an increase in investment outflows[27] - The total cash inflow from financing activities reached ¥414,450,344.29, significantly up from ¥40,111,147.60 in the same period last year[27] - The net cash flow from financing activities was ¥365,916,650.78, compared to ¥27,745,231.01 in the previous year, showing a substantial increase[27] - The net increase in cash and cash equivalents for the period was ¥385,739,518.52, compared to ¥14,568,739.94 in the previous year[27] - The ending balance of cash and cash equivalents was ¥805,044,185.42, a significant rise from ¥396,571,276.41 at the end of the same period last year[27] Assets and Liabilities - Total assets increased by 28.23% to CNY 1,705,713,064.18 from CNY 1,330,174,616.17 at the end of the previous year[5] - The total assets of the company increased to RMB 1,705,713,064.18, up from RMB 1,330,174,616.17 at the beginning of the year, representing a growth of approximately 28.2%[19] - The company's total current assets reached RMB 1,318,128,895.02, compared to RMB 956,446,085.23 at the start of the year, indicating a growth of approximately 37.9%[20] - Total liabilities as of Q1 2022 amounted to CNY 828,362,824.84, compared to CNY 522,967,375.29 in the same period last year[23] - The total liabilities of the company were not explicitly stated, but the increase in current liabilities indicates a potential shift in financial strategy[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,029[12] - The company’s weighted average return on equity was 2.51%, slightly up from 2.45% in the previous year[5] - Total equity attributable to shareholders of the parent company was CNY 861,297,792.12, up from CNY 791,384,719.19 in Q1 2021[23] Research and Development - Research and development expenses rose by 23.66% to CNY 2,041,330.57, reflecting increased investment in R&D[11] Borrowings and Financing - The company experienced a 200.00% increase in short-term borrowings, totaling CNY 150,000,000.00, primarily due to increased bank loans[10] - Short-term borrowings increased to RMB 150,000,000.00 from RMB 50,000,000.00, reflecting a 200% rise[20] - The company issued convertible bonds totaling RMB 27,600,000.00, with 2,760,000 bonds issued at a face value of RMB 100.00 each, aimed at supporting strategic development[17] - The company plans to enhance its core competitiveness through strategic investments funded by the proceeds from the convertible bonds[17] - The company is focused on long-term high-quality growth, supported by the issuance of convertible bonds and strategic investments in its main products[17] Inventory and Receivables - Inventory levels increased to RMB 74,324,549.40 from RMB 66,765,198.12, showing a growth of approximately 11.6%[20] - Accounts receivable decreased slightly to RMB 350,821,704.95 from RMB 361,350,459.45, a decline of about 2.9%[19] Earnings Per Share - The company reported a basic earnings per share of CNY 0.2300, an increase of 11.11% from CNY 0.2070[5] - Earnings per share for Q1 2022 was CNY 0.2300, compared to CNY 0.2070 in Q1 2021, reflecting a 11.66% increase[24] Audit Information - The company did not conduct an audit for the first quarter report[28]

Financial Performance - The company's operating revenue for 2021 was ¥887,484,877.11, representing a 32.40% increase compared to ¥670,312,981.62 in 2020[31]. - The net profit attributable to shareholders for 2021 was ¥93,169,906.99, up 17.77% from ¥79,115,001.83 in 2020[31]. - The net profit after deducting non-recurring gains and losses was ¥93,614,851.91, a 29.34% increase from ¥72,381,389.03 in 2020[31]. - The net cash flow from operating activities was ¥116,035,587.65, reflecting a 25.80% increase compared to ¥92,238,027.19 in 2020[31]. - The total assets at the end of 2021 were ¥1,330,174,616.17, a 14.42% increase from ¥1,162,548,834.54 at the end of 2020[32]. - The net assets attributable to shareholders increased by 9.80% to ¥791,384,719.19 at the end of 2021 from ¥720,776,959.33 at the end of 2020[32]. - The basic earnings per share for 2021 were ¥1.09, an increase of 18.48% from ¥0.92 in 2020[31]. - The diluted earnings per share also stood at ¥1.09, reflecting the same growth of 18.48% compared to ¥0.92 in 2020[31]. - The weighted average return on equity was 12.41%, up from 11.37% in 2020, indicating improved profitability[31]. - The company achieved an annual revenue of ¥887,484,877.11, representing a 32.40% increase compared to the previous year[80]. - The net profit attributable to shareholders reached ¥93,169,906.99, a growth of 17.77% year-over-year, while the net profit after deducting non-recurring gains and losses increased by 29.34% to ¥93,614,851.91[80]. Product Development and Innovation - The company is actively developing a "coronavirus 3CL protease inhibitor" project in collaboration with Shaanxi University of Science and Technology, currently in the preclinical research phase[12]. - The company has launched health products such as "Panlong Seven toothpaste" and face masks, which have received positive consumer feedback[12]. - The company is pursuing a strategy of "specialized, refined, unique, and new" to enhance its research and development capabilities[11]. - The company plans to invest approximately 3% of its annual revenue into R&D to enhance its innovative capabilities[57]. - The company has established a research institute to foster collaboration with academic institutions and healthcare organizations, focusing on a "frontier grasping and imitation-innovation" R&D strategy[57]. - The company has developed 10 health products and 13 traditional Chinese medicine formula granules during the reporting period[83]. - The company has completed the formulation and quality research for several products, including various vitamin and health supplements, which are set to be filed with the provincial market bureau[84]. - The company has made significant progress in the research of the pharmacological mechanisms of Panlong Seven tablets, resulting in 6 published papers[86]. Market Position and Strategy - The company is focusing on the modernization of traditional Chinese medicine and aims to strengthen its core business in the pharmaceutical industry[10]. - The company is positioned to benefit from the increasing market demand for traditional Chinese medicine as the industry receives unprecedented policy support[41]. - In 2021, the company achieved a market share of 7.24% for its leading product, Panlong Qipian, ranking second in the market for traditional Chinese medicine for musculoskeletal diseases[49]. - The company’s main product, Panlong Qipian, is a unique national patent and a Class A medical insurance product, consisting of 29 herbal ingredients, which enhances its market competitiveness[48]. - The company is expanding its product range into the health industry, including oral health, functional foods, and medical devices, under a "one body, two wings" strategy[69]. - The company is actively pursuing a strategy of "integration of production, research, and sales" to enhance its market competitiveness and long-term sustainability[76]. Talent Development and Organizational Structure - The company emphasizes the importance of talent development and aims to optimize its talent structure for better organizational vitality[13]. - The company has established a training plan focusing on talent development, with an emphasis on internal training and a structured human resources education system[200]. - The company has a competitive salary policy, ensuring internal fairness and external competitiveness, with various components including basic salary, performance pay, and bonuses[199]. - The company has expanded its talent pool through training, recruitment, and employee stock ownership plans to support sustainable growth[134]. Compliance and Governance - The company emphasizes compliance with laws and regulations, enhancing internal control systems to mitigate risks from industry policy changes[138]. - The company has established a decision-making and management system that ensures compliance and protects investor rights[144]. - The company has a clear governance structure, with decision-making bodies operating independently from major shareholders[162]. - The company has established independent personnel management systems, ensuring that senior management does not hold positions in related enterprises[159]. - The company maintains a robust internal control audit process, reflecting the execution of its internal control systems[155]. Social Responsibility and Community Engagement - The company is actively participating in social responsibility initiatives, including poverty alleviation and community support[137]. - The company is committed to green development, implementing high standards for environmental management and resource efficiency[135]. Financial Management and Investment - The company has established a complete and independent financial accounting system, ensuring compliance with relevant regulations and the ability to make independent financial decisions[161]. - The company has initiated a convertible bond project to enhance production capacity and optimize product structure, approved by the CSRC in October 2021[89]. - The company has received 3 provincial-level platform approvals and 3 honors during the reporting period[84]. - The company has CNY 48.2834 million of unutilized raised funds, including CNY 10.2834 million in a special account and CNY 38 million in fixed deposits[125].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 陕西盘龙药业集团股份有限公司 陕西盘龙药业集团股份有限公司 2021 年第三季度报告 2021 年第三季度报告 证券代码：002864 证券简称：盘龙药业 公告编号：2021-077 陕西盘龙药业集团股份有限公司 2021 年第三季度报告 (二)非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 | 本报告期金额 | 年初至报告期期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 计入当期损益的政府补助（与公司正常经营业务 密切相关，符合国家政策规定、按照一定标准定 额或定量持续享受的政府补助除外） | 620, ...

陕西盘龙药业集团股份有限公司 2021 年半年度报告全文 陕西盘龙药业集团股份有限公司 2021 年半年度报告 2021 年 08 月 1 陕西盘龙药业集团股份有限公司 2021 年半年度报告全文 董事长致辞 行稳致远 勇于创新 与时代共舞 谢晓林 2021年是十四五开局之年，我们勇立于百年未有之大变局的潮头，迎来了党的百年华诞！ 二十多年前，我们白手起家，在自有资金短缺、厂房设施简陋、设备严重落后的情况下， 披荆斩棘，开启山林，跃马扬鞭，改革改制，为盘龙药业的发展打下坚实的基础。 二十余年来，我们营销转型、科技创新、规范管理，踏着一步又一步坚实的步伐，奏响 了一曲又一曲蓬勃发展的乐章，打造了一个不断超越、持续增长的现代化医药企业集团，走 出了一条改革创新的发展之路，肩负起了推动国家中医药伟大事业发展，助力脱贫攻坚的光 荣使命。 四年前，我们在深圳证券交易所主板上市，成为商洛本土乃至全国深度贫困县的第一家 上市企业，也由此跨入了资本市场的阵营，使我们站在了一个更高的起点。从秦岭大山中走 出，开启了盘龙从地方走向全国的新征程，进入了盘龙药业的快速成长之路。 上市以来，企业经营业绩节节攀升，营收增长近 2.19 ...

陕西盘龙药业集团股份有限公司 2021 年第一季度报告全文 陕西盘龙药业集团股份有限公司 2021 年第一季度报告 2021 年 04 月 1 陕西盘龙药业集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人谢晓林、主管会计工作负责人祝凤鸣及会计机构负责人(会计主 管人员)程茜声明：保证季度报告中财务报表的真实、准确、完整。 2 陕西盘龙药业集团股份有限公司 2021 年第一季度报告全文 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 174,868,139.36 | 81,187,108.55 | 115.39% | | 归属于上市公司股东的净利润（元） | 17,738,938.74 | ...

Financial Performance - The company reported a cash dividend of 1.5 RMB per 10 shares for a total of 85,548,100 shares, amounting to a total cash distribution of approximately 12.83 million RMB[6]. - The company's operating revenue for 2020 was ¥670,312,981.62, representing a 9.77% increase compared to ¥610,636,793.21 in 2019[6]. - The net profit attributable to shareholders for 2020 was ¥79,115,001.83, a 10.22% increase from ¥71,778,896.72 in 2019[6]. - The net cash flow from operating activities increased by 35.87% to ¥92,238,027.19 in 2020, up from ¥67,886,531.13 in 2019[6]. - The total assets at the end of 2020 were ¥1,162,548,834.54, a 25.16% increase from ¥928,877,916.40 at the end of 2019[6]. - The basic earnings per share for 2020 were ¥0.92, up 10.84% from ¥0.83 in 2019[6]. - The net profit after deducting non-recurring gains and losses for 2020 was ¥72,381,389.03, an 11.13% increase from ¥65,134,853.64 in 2019[6]. - The total operating revenue for 2020 was ¥670,312,981.62, representing a year-on-year increase of 9.77% compared to ¥610,636,793.21 in 2019[71]. - The pharmaceutical manufacturing and sales segment accounted for ¥667,417,461.57, or 99.57% of total revenue, with a year-on-year growth of 9.64%[72]. - The gross profit margin for pharmaceutical manufacturing and sales was 62.31%, down from the previous year by 7.20%[74]. Product Development and Innovation - The company has 41 products included in the 2020 National Medical Insurance Catalog, with 21 classified as Category A and 20 as Category B[28]. - The company has obtained the production license for liquid disinfectants during the pandemic, enhancing its product offerings[28]. - The company has a total of 74 drug production approval numbers and 1 health food product, indicating a diverse product portfolio[28]. - The company has four exclusive products, including Panlong Qipian, which is a national medical insurance Class A product composed of 29 traditional Chinese herbs, showing significant therapeutic effects for conditions like rheumatoid arthritis and osteoarthritis[30]. - The company’s proprietary product, Jin Yin Li Dan Capsules, has been proven to effectively prevent fatty liver and treat gallstone-related issues, with a high content of active ingredients due to its unique preparation process[31]. - The company has improved the production process of Kebi Retipian, transitioning from a tablet to a film-coated tablet, enhancing the stability of the medicine and patient compliance[32]. - The company’s product lineup includes a variety of traditional Chinese medicine formulations, each targeting specific health issues, thereby diversifying its market offerings[30]. - The company has developed a diverse product range, including traditional Chinese medicine and health products, with successful launches of new products like Panlong Qigao toothpaste and Panlong Qijiao gel[48]. - The company has initiated research on traditional Chinese medicine formula granules, completing small-scale studies on ten different herbal ingredients[61]. Market Strategy and Expansion - The company is expanding its retail team to enhance the dual-channel marketing strategy, focusing on both clinical and retail markets[35]. - The company is leveraging the opportunities presented by the COVID-19 pandemic to enhance the market scale of traditional Chinese medicine and related products[37]. - The company is actively pursuing market expansion and strategic acquisitions to enhance its competitive edge in the healthcare industry[46]. - The company plans to expand its market share by leveraging its brand advantages and enhancing the promotion of its core products[41]. - The company is focusing on expanding its market network and enhancing its management and talent development to support its strategic goals[59]. - The company plans to expand its market presence in the health industry and develop online sales channels for health products[118]. Research and Development - The company has established the Panlong Pharmaceutical Research Institute to enhance its R&D capabilities and strengthen its market competitiveness[42]. - The company has formed partnerships with several universities and research institutions to enhance R&D capabilities and ensure continuous innovation[48]. - The company has committed to enhancing its core competitive advantages and expanding its market presence to achieve dual improvements in revenue and profitability[144]. - Research and development (R&D) expenditure amounted to ¥12.97 million, accounting for 1.94% of total revenue, down from 2.14% in 2019[90]. - The company has accelerated the development of generic drugs, completing methodology establishment for the genotoxic impurities of Celecoxib capsules[84]. Corporate Governance and Compliance - The company has maintained its commitment to ensuring the accuracy and completeness of its financial reports, with key executives affirming the integrity of the annual report[4]. - The company has not engaged in any related party transactions during the reporting period[156]. - The company has not experienced any significant accounting errors or changes in accounting policies during the reporting period[148]. - The company has maintained a continuous relationship with its auditing firm for 9 years, ensuring consistent oversight[152]. - The company will continue to strengthen its governance structure and ensure compliance with regulations to protect investors' rights[118]. Social Responsibility and Community Engagement - The company has engaged in poverty alleviation efforts, benefiting over 7,520 individuals through various agricultural initiatives[67]. - The company has cumulatively paid over CNY 600 million in taxes, contributing to the economic development of impoverished areas[169]. - The company plans to continue expanding its traditional Chinese medicine industry to support poverty alleviation efforts[176]. - The company has committed to ongoing support for education and social welfare initiatives, including donations to charitable organizations[176]. Shareholder Returns and Capital Management - The proposed cash dividend distribution is CNY 1.50 per 10 shares, totaling CNY 12,832,215.00, which represents 16.22% of the net profit attributable to shareholders[129]. - The total distributable profit at the end of 2020 was CNY 329,024,835.27, with the cash dividend accounting for 100% of the profit distribution[127]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during profit distribution, considering its financial status and operational needs[127]. - The company plans to use its own funds for future share repurchases, with a total amount not less than 10 million RMB and not exceeding 20 million RMB[189]. - The company has established a cash dividend policy that prioritizes cash dividends over stock dividends, ensuring better returns for shareholders[144].

陕西盘龙药业集团股份有限公司 2020 年第三季度报告全文 陕西盘龙药业集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 陕西盘龙药业集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人谢晓林、主管会计工作负责人祝凤鸣及会计机构负责人(会计主 管人员)程茜声明：保证季度报告中财务报表的真实、准确、完整。 2 陕西盘龙药业集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,120,451,276.01 | 928,877,916.40 | | 20.62% | | 归属于上市公司股东的净资产 | 707,68 ...